Aurinia Pharmaceuticals Inc. (TSE:AUP – Get Free Report) (NASDAQ:AUPH) was down 3.5% during mid-day trading on Monday . The stock traded as low as C$16.41 and last traded at C$16.76. Approximately 4,611,683 shares were traded during trading, an increase of 1,906% from the average daily volume of 229,895 shares. The stock had previously closed at C$17.37.
Aurinia Pharmaceuticals Trading Down 3.5 %
The company has a debt-to-equity ratio of 2.69, a current ratio of 11.93 and a quick ratio of 11.02. The firm has a market capitalization of C$2.15 billion and a price-to-earnings ratio of -11.32. The firm has a 50 day moving average of C$16.76.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Featured Stories
- Five stocks we like better than Aurinia Pharmaceuticals
- Stock Splits, Do They Really Impact Investors?
- Why Block’s Key Components Make It a Solid Investment Choice
- 3 Monster Growth Stocks to Buy Now
- Is Applied Digital’s Stock Set to Surge With NVIDIA’s Backing?
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- 4 Reasons to Consider Adding General Mills to Your Portfolio
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
